is a biotechnology company focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. Analysts have a BUY recommendation on the stock with a $9.5/share price target. The goal of the strategic review was to assess TYME’s current pipeline, explore additional development opportunities, examine drug development process and determine how best to maximize the efficiency of the Company’s capital expenditures. On June 10, 2021, TYME executive management team will provide an updated business plan derived from the conclusions of the Company’s comprehensive strategic review that was conducted over the past several months. TYME may use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to its own. On February 8, 2021, TYME announced that it closed its previously announced registered direct offering of 40M shares of its common stock at a purchase price of $2.50/share. Proof-of-concept trials to start in 2H2020. When the patent was announced TYME jumped almost 300%. The company's TYME-19 patented COVID-19 therapy is formulated to overcome any mutations of the virus. TYME's 2021 ASCO abstract for drug candidate SM-88 in Ewing and other sarcomas reveals stable disease was achieved in 75.0% (6/8 with available data) with no serious drug-related AEs.Ĭlinical results thus far from trials of SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas, breast, and other cancers have demonstrated the significant potential of the company's CMBT pipeline. Some recent and future catalysts that may drive the stock to the $2.50 per share territory (as reported on Jin Seeking Alpha). The 52-week low is $0.85 per share.īased on the options action today, this stock may be poised for a break-out, sooner than later. The 52-week high on TYME is $4.99 per share. It points to the fact that someone was buying up the June monthly $2 strike calls with the view that they believe that TYME will be trading north of $2 in just 17 days. Considering the open interest on these options is only 3,050 contracts, the volume of 2,000 contract today was significant. Today's options action saw the J$2 strike call increase trade 2,000+ contracts tripling the price of the contracts from $0.05 to $0.15 per contract. Since May 13, 2021, the stock price has steadily risen from a price of $1.13 to a high price today of $1.68 per share. Tyme Technologies Inc ( TYME ) had some unusual options activity today, Tuesday, June 1, 2021.
0 kommentar(er)
